TaiMed Biologics (ROCO:4147) Beta: 0.0434 (As of Jul. 11, 2026)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.90
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics Beta?

TaiMed Biologics ROCO:4147 55 Beta is 0.0434 as of Jul. 11, 2026. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-11), TaiMed Biologics's Beta is 0.0434.


TaiMed Biologics  (ROCO:4147) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


TaiMed Biologics Beta Related Terms


TaiMed Biologics Beta Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics Beta Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.78 0.09 0.28 0.00

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.00 0.00 0.00 0.00

ROCO:4147 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, TaiMed Biologics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Beta distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Beta falls into.


ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0434 mean?
TaiMed Biologics (ROCO:4147) has a Beta of 0.0434 as of Jul. 11, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for TaiMed Biologics and its competitors.
Is TaiMed Biologics' Beta too high?
TaiMed Biologics' current Beta is 0.0434. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Beta compare to VRTX and REGN?
TaiMed Biologics' Beta of 0.0434 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for TaiMed Biologics and its competitors. TaiMed Biologics's current Beta is 0.0434. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Beta is 0.0434. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Beta is 0.0434 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • Beta: 0.0434
  • GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.90
GF Value